ATE264304T1 - Dihydronaphthalinderivate und verfahren zur herstellung derselben - Google Patents

Dihydronaphthalinderivate und verfahren zur herstellung derselben

Info

Publication number
ATE264304T1
ATE264304T1 AT98945556T AT98945556T ATE264304T1 AT E264304 T1 ATE264304 T1 AT E264304T1 AT 98945556 T AT98945556 T AT 98945556T AT 98945556 T AT98945556 T AT 98945556T AT E264304 T1 ATE264304 T1 AT E264304T1
Authority
AT
Austria
Prior art keywords
inhibiting activity
cancer
dihydronaphthaline
derivatives
producing
Prior art date
Application number
AT98945556T
Other languages
English (en)
Inventor
Rolf Wolfgang Hartmann
Bertil Wachall
Makoto Yoshihama
Masamichi Nakakoshi
Shin Nomoto
Yoshikazu Ikeda
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Application granted granted Critical
Publication of ATE264304T1 publication Critical patent/ATE264304T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
AT98945556T 1997-10-02 1998-10-01 Dihydronaphthalinderivate und verfahren zur herstellung derselben ATE264304T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP28426397 1997-10-02
PCT/JP1998/004426 WO1999018075A1 (fr) 1997-10-02 1998-10-01 Nouveaux composes a base de dihydronaphtalene et leur procede de production

Publications (1)

Publication Number Publication Date
ATE264304T1 true ATE264304T1 (de) 2004-04-15

Family

ID=17676271

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98945556T ATE264304T1 (de) 1997-10-02 1998-10-01 Dihydronaphthalinderivate und verfahren zur herstellung derselben

Country Status (17)

Country Link
EP (1) EP1028110B1 (de)
KR (1) KR20000069426A (de)
CN (1) CN1117732C (de)
AT (1) ATE264304T1 (de)
AU (1) AU743405B2 (de)
CA (1) CA2298527A1 (de)
DE (1) DE69823222T2 (de)
DK (1) DK1028110T3 (de)
ES (1) ES2218853T3 (de)
FI (1) FI20000207A (de)
HU (1) HUP0004037A3 (de)
IL (1) IL133483A0 (de)
NO (1) NO315044B1 (de)
NZ (1) NZ501822A (de)
RU (1) RU2203890C2 (de)
WO (1) WO1999018075A1 (de)
ZA (1) ZA988954B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100287366B1 (ko) 1997-11-24 2001-04-16 윤순조 엠피이지 방식을 이용한 휴대용 음향 재생장치 및 방법
US7001926B2 (en) 2000-03-10 2006-02-21 Oxigene, Inc. Tubulin binding agents and corresponding prodrug constructs
TWI283669B (en) * 1999-06-10 2007-07-11 Allergan Inc Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
US6849656B1 (en) 1999-09-17 2005-02-01 Baylor University Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
JP4616454B2 (ja) * 1999-10-22 2011-01-19 武田薬品工業株式会社 1−置換フェニル−1−(1h−イミダゾール−4−イル)アルコール類、その製造法および用途
DE60027034T2 (de) 1999-10-22 2006-11-09 Takeda Pharmaceutical Co. Ltd. 1-substituierte-phenyl-1-(1h-imidazol-4-yl)alkohole, verfahren zu deren herstellung sowie deren verwendung
JP4520012B2 (ja) * 1999-10-22 2010-08-04 武田薬品工業株式会社 1−置換−1−(1h−イミダゾール−4−イル)メタノール類
JP2004505888A (ja) 2000-03-10 2004-02-26 ベイラー・ユニバーシテイ チューブリン結合リガンドおよび対応するプロドラッグ構造
US7091240B2 (en) 2000-03-10 2006-08-15 Oxigene, Inc. Tubulin binding ligands and corresponding prodrug constructs
MY134929A (en) 2000-11-17 2008-01-31 Takeda Pharmaceutical Novel imidazole derivatives, production method thereof and use thereof
ATE502030T1 (de) 2000-11-20 2011-04-15 Takeda Pharmaceutical Imidazolderivate, verfahren zu deren herstellung und deren verwendung
DE60139639D1 (de) 2000-12-08 2009-10-01 Takeda Pharmaceutical Substituierte thiazolderivate mit 3-pyridylgruppen, verfahren zu deren herstellung und deren verwendung
WO2004073602A2 (en) * 2002-01-25 2004-09-02 Pharmacia Corporation Aldosterone blocker therapy to prevent or treat inflammation-related disorders
US7456214B2 (en) 2004-05-03 2008-11-25 Baylor University Chromene-containing compounds with anti-tubulin and vascular targeting activity
UA105794C2 (uk) 2009-06-26 2014-06-25 Новартіс Аг 1,3-ДИЗАМІЩЕНІ ПОХІДНІ ІМІДАЗОЛІДИН-2-ОНУ ЯК ІНГІБІТОРИ Cyp17
WO2012018948A2 (en) 2010-08-04 2012-02-09 Pellficure Pharmaceuticals, Inc. Novel treatment of prostate carcinoma
JP2013537210A (ja) 2010-09-16 2013-09-30 ノバルティス アーゲー 17α−ヒドロキシラーゼ/C17,20−リアーゼ阻害剤
JP6002210B2 (ja) 2011-04-28 2016-10-05 ノバルティス アーゲー 17α−ヒドロキシラーゼ/C17,20−リアーゼ阻害剤
EP2968219B1 (de) 2013-03-14 2019-04-24 Pellficure Pharmaceuticals, Inc. Neuartige therapie gegen prostatakarzinome
US10093620B2 (en) 2014-09-12 2018-10-09 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
AU2017350690A1 (en) 2016-10-24 2019-06-13 Pellficure Pharmaceuticals Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5681566A (en) * 1979-12-05 1981-07-03 Yoshitomi Pharmaceut Ind Ltd Imidazole derivative
ZA825413B (en) * 1981-08-26 1983-06-29 Pfizer Thromboxane synthetase inhibitors, processes for their production, and pharmaceutical compositions comprising them
US4540705A (en) * 1983-03-14 1985-09-10 Sterling Drug Inc. Antidepressant imidazolines and related compounds
PH22076A (en) * 1983-08-25 1988-05-20 Daiichi Seiyaku Co Benzocycloalkane derivative
JPS61186348A (ja) * 1985-02-14 1986-08-20 Dai Ichi Seiyaku Co Ltd ナフタレン誘導体
DE3508905A1 (de) * 1985-03-13 1986-09-18 Hoechst Ag, 6230 Frankfurt Neue imidazolylverbindungen und verfahren zu ihrer herstellung
JPH06166674A (ja) * 1992-12-01 1994-06-14 Tokyo Tanabe Co Ltd テトラリン化合物
JP3338905B2 (ja) * 1993-05-13 2002-10-28 帝国臓器製薬株式会社 6位置換ステロイド誘導体
HUT75871A (en) * 1993-09-30 1997-05-28 Yamanouchi Co Azole derivatives and pharmaceutical compositions thereof
FR2787451B1 (fr) * 1998-12-18 2001-01-26 Adir Nouveaux composes imidazoliniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
DE69823222D1 (de) 2004-05-19
HUP0004037A3 (en) 2002-03-28
EP1028110A1 (de) 2000-08-16
FI20000207A (fi) 2000-02-01
NZ501822A (en) 2001-12-21
AU9281098A (en) 1999-04-27
CN1268120A (zh) 2000-09-27
CN1117732C (zh) 2003-08-13
ZA988954B (en) 1999-04-12
DE69823222T2 (de) 2005-04-14
CA2298527A1 (en) 1999-04-15
WO1999018075A1 (fr) 1999-04-15
NO20001289L (no) 2000-03-10
NO20001289D0 (no) 2000-03-10
NO315044B1 (no) 2003-06-30
HUP0004037A2 (hu) 2001-10-28
EP1028110A4 (de) 2001-05-23
DK1028110T3 (da) 2004-07-19
ES2218853T3 (es) 2004-11-16
KR20000069426A (ko) 2000-11-25
IL133483A0 (en) 2001-04-30
EP1028110B1 (de) 2004-04-14
RU2203890C2 (ru) 2003-05-10
AU743405B2 (en) 2002-01-24

Similar Documents

Publication Publication Date Title
ATE264304T1 (de) Dihydronaphthalinderivate und verfahren zur herstellung derselben
YU596A (sh) Estrogen agonisti/antagonisti
DK1019060T3 (da) Androgensynteseinhibitorer
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
TR200103273T2 (tr) Hemisentetik yöntem ve yeni bileşimler.
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
ATE263157T1 (de) Nematizide trifluorbutene
MY120090A (en) Chemical compounds.
ATE231724T1 (de) Kombinationstherapie für die behandlung von psychosen
ATE271058T1 (de) Mycophenol bisphosponatverbindungen
DE69905476D1 (en) Phosphonsaürederivate als ptp-1b-inhibitoren
TR200001012T2 (tr) Yeni ariloksi-alkil-dialkilaminler.
BG103548A (en) Vitronectine receptor antagonists
MXPA04004939A (es) 5,5??,6,6??,7,7??,8,8??-octahidro-2,2??-binaftoles 3-alquilados y 5,5??,6,6??,7,7??,8,8??-octahidro-2,2??-binaftoles 3,3??-dialquilados y procesos para su fabricacion.
DE60112330D1 (en) Pyrazolopyridinderivate
PT989973E (pt) Calconas possuindo actividade antiproliferativa
MXPA01008347A (es) Compuestos quimicos.
AU3029297A (en) 7alpha-(5-methylaminopentyl)-estratrienes, process for their production, pharmaceutical preparations that contain these 7alpha-(5-methylaminopentyl)-estratrienes as well as their use for the production of pharmaceutical agents
MY133390A (en) Azabicyclic 5ht1 receptor ligands
BR9902084A (pt) Heterociclos.
SE9604582D0 (sv) Novel compounds
SE9504618D0 (sv) New Compounds
DE69724548D1 (de) Substituierte 2,3-Aryl-Benzothiophene und ihre östrogene Aktivität
BG107553A (en) Aminoalkenylbenzoyl-benzofuran or benzothiophene derivatives, methods for preparing same and compositions containing same
CO5150221A1 (es) Nuevas 3-fenoxi- y 3-fenilalquiloxi-2-fenil-propilaminas sustituidas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1028110

Country of ref document: EP

REN Ceased due to non-payment of the annual fee